Payment overview · 2025
General Payments
$623.58
29 reported records · 13 companies
Healthcare provider profile · identity verified
Mairaj Uddin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SEMINOLE, FL · NPI 1144329285
Verified facts
What the public records show
CMS Open Payments records show Mairaj Uddin, M.D. received $623.58 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.22 | 23.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.89 | 16.5% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $90.28 | 14.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.85 | 11.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.62 | 5.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.42 | 5.0% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.72 | 4.9% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $25.81 | 4.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.58 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.16 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.36 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.53 | 2.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.14 | 1.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.58 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $102.89 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $98.61 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $90.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.85 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.85 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.61 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.14 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 121 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
121 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 465 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 129 |
| Methylprednisolone | Methylprednisolone | 333 | 255 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 309 | 82 |
| Losartan Potassium | Losartan Potassium | 298 | 114 |
| Tramadol Hcl | Tramadol Hcl | 258 | 85 |
| Metformin Hcl | Metformin Hcl | 255 | 90 |
| Lisinopril | Lisinopril | 240 | 83 |
| Azithromycin | Azithromycin | 239 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 98 |
| Omeprazole | Omeprazole | 231 | 101 |
| Baclofen | Baclofen | 224 | 117 |
| Gabapentin | Gabapentin | 224 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 69 |
| Prednisone | Prednisone | 177 | 111 |
| Temazepam | Temazepam | 173 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 75 |
| Furosemide | Furosemide | 171 | 61 |
| Alprazolam | Alprazolam | 170 | 55 |
| Cephalexin | Cephalexin | 163 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 53 |
| Benzonatate | Benzonatate | 141 | 103 |
| Meloxicam | Meloxicam | 137 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 68 |
| Eliquis | Apixaban | 121 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 45 |
| Carvedilol | Carvedilol | 107 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 46 |
| Glipizide | Glipizide | 104 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 38 |
| Simvastatin | Simvastatin | 100 | 38 |
| Trazodone Hcl | Trazodone Hcl | 98 | 43 |
| Lorazepam | Lorazepam | 92 | 23 |
| Montelukast Sodium | Montelukast Sodium | 86 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 29 |
| Diazepam | Diazepam | 79 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 73 | 56 |
| Famotidine | Famotidine | 73 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 20 |
| Allopurinol | Allopurinol | 71 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 29 |
| Sertraline Hcl | Sertraline Hcl | 71 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 62 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 22 |
| Warfarin Sodium | Warfarin Sodium | 56 | 13 |
| Clonazepam | Clonazepam | 55 | 11 |
| Pregabalin | Pregabalin | 55 | 18 |
| Finasteride | Finasteride | 54 | 23 |
| Tadalafil | Tadalafil | 50 | 14 |
| Buspirone Hcl | Buspirone Hcl | 47 | 28 |
| Celecoxib | Celecoxib | 46 | 21 |
| Donepezil Hcl | Donepezil Hcl | 46 | 21 |
| Clonidine Hcl | Clonidine Hcl | 45 | 31 |
| Ozempic | Semaglutide | 45 | 13 |
| Ibuprofen | Ibuprofen | 43 | 17 |
| Mirtazapine | Mirtazapine | 42 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Potassium Chloride | Potassium Chloride | 42 | 16 |
| Atenolol | Atenolol | 41 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 41 | 17 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 25 |
| Lovastatin | Lovastatin | 39 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Glimepiride | Glimepiride | 38 | 15 |
| Ondansetron Odt | Ondansetron | 38 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 14 |
| Metronidazole | Metronidazole | 37 | 31 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 14 |
| Januvia | Sitagliptin Phosphate | 33 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 15 |
| Ketoconazole | Ketoconazole | 30 | 22 |
| Lactulose | Lactulose | 30 | 18 |
| Memantine Hcl | Memantine Hcl | 30 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 20 |
| Mupirocin | Mupirocin | 29 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 19 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 25 | 21 |
| Nitroglycerin | Nitroglycerin | 25 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Nystatin | Nystatin | 23 | 17 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | 13 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 12 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | 15 |
| Silver Sulfadiazine | Silver Sulfadiazine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | 12 |
| Valacyclovir | Valacyclovir Hcl | 17 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Folic Acid | Folic Acid | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.58 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ATRICLIP LAA EXCLUSION SYSTEM, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KEVZARA, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, WATCHMAN Access System, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error